The Expression of CD90/Thy-1 in Hepatocellular Carcinoma: An In Vivo and In Vitro Study (original) (raw)
Figure 4
The potency of DOX resistance of the JHH-6 subpopulations CD90+ and CD90-.
A. Cells viability against DOX (0-40 µg/ml) for 24 hours assessed by MTT assay. Non-treated cells were considered as 100% viability (Students’ t test *p<0.05). The data represented the mean ± SD of three independent experiments. B. The mRNA and protein expression of DOX-related ABC transporters ABCB1, ABCCC1, and ABCG2 genes (Students’ t test *p<0.05 compared to CD90-). Low panel: WB analysis of each proteins ABCG2 (72 kDa), ABCB1 (170-190 kDa), and ABCC1 (140 kDa) together with ATP1A1 membrane protein (112 KDa).